NEBULIZERS AND COVID-19: AEROSOL GENERATION VS. AEROSOL DISPERSION
Journal of Aerosol Medicine and Pulmonary Drug Delivery
; 35(2):A3, 2022.
Article
in English
| EMBASE | ID: covidwho-1815949
ABSTRACT
Introduction:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the global pandemic of coronavirus disease 2019 (COVID-19), has afflicted more than 245 million people worldwide and caused more than 5 million deaths (1). COVID-19 primarily affects the respiratory tract and infected persons generate respiratory droplets and aerosols containing the virus that transmit the infection to susceptible hosts (2). Patients with COVID- 19 need inhaled therapies, either for pre-existing respiratory diseases or because of new onset respiratory distress and hypoxemia in patients with no previous pulmonary problems. Aerosolized therapies increase particle concentrations in the vicinity of patients receiving such treatments (3, 4). Inhalers (pMDIs, DPIs and SMIs) have a very low risk of contamination and the risk of spreading infection with those devices is largely due to ''bioaerosols'' generated by the patient during breathing, speaking, coughing or sneezing (2,5,6). In contrast, nebulizers, especially those that are operated continuously, release ''fugitive emissions'' that could remain in the indoor environment.
adult; aerosol; breathing; conference abstract; contamination; controlled study; coronavirus disease 2019; coughing; human; hypoxemia; indoor environment; inhaler; nebulizer; nonhuman; pandemic; respiratory distress; respiratory droplets and aerosols; respiratory tract disease; Severe acute respiratory syndrome coronavirus 2; sneezing; speech
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Journal of Aerosol Medicine and Pulmonary Drug Delivery
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS